USPTO serial 79179556
HUMABODY
Reviewed by CopyMark Law Group
Reg. 5158366Status 707Renewal
- Filing date
- Status date
- Registration date
- Mar 14, 2017
- Examiner
- POLLACK, ALISON FRIEDBERG
- Law office
- Historical data usage
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with HUMABODY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $548*
Plus Government fees of $1,300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Rebecca Liebowitz
Rebecca Liebowitz VENABLE LLPP.O. BOX 34385WASHINGTON, DC 20043UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | chemicals used in industry and science; [ chemical test kits for in vitro testing for laboratory research purposes; ] biochemicals, namely, monoclonal antibodies and antibody fragments all being proteins for in vitro scientific and laboratory research use; biochemicals, namely, monoclonal antibodies and antibody fragments for in vitro scientific and laboratory research use; antibodies and antibody fragments all being protein in raw material form for scientific research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for scientific and laboratory in vitro diagnostic use; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical and clinical development of therapeutic products | ACTIVE | — |
| 005 | pharmaceutical preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; veterinary preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; therapeutic pharmaceutical preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; antibodies being pharmaceutical preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; antibody fragments being pharmaceutical preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases] ; antibody therapeutics in the nature of therapeutic agents for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; medical diagnostic reagents and veterinary diagnostic reagents in the nature of antibodies and antibody fragments; antibodies and antibody fragments being therapeutic pharmaceuticals for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] and or use in the manufacture of therapeutic products | ACTIVE | — |
| 040 | [ Treatment and transformation of materials for others, namely, the manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing services in the field of chemicals, biologicals, antibodies and antibody fragments; custom manufacture of therapies using antibodies and antibody fragments ] | SECTION 71 - CANCELLED | — |
| 042 | [ Scientific and technological services, namely, scientific research, analysis and testing and research and design in the field of chemicals, biologicals, antibodies and antibody fragments; Scientific laboratory services in the field of antibodies and antibody fragments; research in the field of the development of antibodies and antibody fragments; provision of scientific information in the field of antibodies and antibody fragments for medical and veterinary purposes; engineering of antibodies and antibody fragments; scientific services, namely, drug discovery, preclinical and clinical development of therapeutic products; consultancy services relating thereto, namely, consulting in the field of antibody and antibody fragment design ] | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Crescendo Biologics Limited
- Other trademarks owned by Crescendo Biologics Limited
- Other trademarks owned by Crescendo Biologics Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named HUMABODY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 14, 2026 | REM4 | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED | — |
| Jun 20, 2025 | INNP | PARTIAL INVALIDATION PROCESSED BY THE IB | — |
| May 12, 2025 | INPS | PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| May 12, 2025 | INPC | INVALIDATION PROCESSED | — |
| May 12, 2025 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Feb 27, 2025 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Dec 12, 2024 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Nov 8, 2024 | RHRD | RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED | — |
| Jun 27, 2024 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Jun 27, 2024 | 71.P | REGISTERED - PARTIAL SEC 71 ACCEPTED | — |
| May 7, 2024 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Oct 27, 2023 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Sep 13, 2023 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Aug 19, 2023 | RHRD | RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED | — |
| Mar 14, 2022 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Dec 7, 2017 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 14, 2017 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jun 22, 2017 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jun 22, 2017 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jun 14, 2017 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 14, 2017 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 3, 2017 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Nov 18, 2016 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Oct 18, 2016 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Sep 20, 2016 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 20, 2016 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 31, 2016 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Aug 31, 2016 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Aug 31, 2016 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 17, 2016 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Aug 9, 2016 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 9, 2016 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 9, 2016 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 9, 2016 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 9, 2016 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 8, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 8, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 8, 2016 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jul 29, 2016 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jul 29, 2016 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jul 29, 2016 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jul 15, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 15, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 15, 2016 | ALIE | ASSIGNED TO LIE | — |
| Jul 11, 2016 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 11, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 1, 2016 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 11, 2016 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 11, 2016 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 8, 2016 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 6, 2016 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 5, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 4, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 4, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 3, 2016 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |